Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Verscend Holding Corp. New York, May 27, 2020 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Verscend Holding Corp. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that it will report financial results for the year ended December 31, 2019, by press release on Thursday, March 12, 2020 at approximately 7:00 a.m. Eastern Time.
PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that data from its Head-to-Head Burn trial was published in the Journal of Burn Care & Research. This abstract was accepted for a podium presentation at the American Burn Association Meeting, which was cancelled due to the COVID-19 pandemic. Eight patients with deep-partial/full thickness burns had a portion of their wounds treated with SkinTE™, an autologous homologous skin construct (AHSC), and the remainder of their burn treated with split-thickness skin grafting. AHSC-treated wounds had graft take and achieved closure by their last follow-up with a single application. There were no AHSC treatment related adverse events. These encouraging data are being used to design a larger burn trial and the Company continues to work with several KOLs to finalize a study protocol.
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today reported results for calendar fourth quarter and year ended December 31, 2019. PolarityTE will host a conference call and webcast with Q&A today, Thursday, March 12, 2020 at 8:00 a.m. Eastern Time. Please see details below.
NEW YORK , Nov. 19, 2019 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty ...
Investors need to pay close attention to PolarityTE (PTE) stock based on the movements in the options market lately.
PolarityTE, Inc. (Nasdaq: PTE) is providing an update on a change to the strategic focus of the Company and the regulatory pathway for the Company’s SkinTE™ product.
PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, is providing an update on actions the Company is taking to best position the business and support the Company’s stakeholders in light of the COVID-19 pandemic, and preliminary First Quarter 2020 results.
Investors need to pay close attention to PolarityTE (PTE) stock based on the movements in the options market lately.
PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today reported financial results for the first calendar quarter of 2020. PolarityTE will host a conference call and webcast today, May 11, 2020 at 8:00 a.m. ET.
PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that the Company’s Board of Directors has restructured the executive team to more appropriately align with traditional management structures, dissolving the Office of the Chief Executive, which had been in place since August 2019. David Seaburg has been appointed Chief Executive Officer of PolarityTE. Richard Hague has assumed the role of President, while maintaining his responsibilities as Chief Operating Officer. Paul Mann, who previously served as Chief Financial Officer, will depart the Company and remain available for consulting purposes through the end of the 2020 fiscal year. Jacob Patterson, current Vice President of Finance, will serve as interim Chief Financial Officer.
If you're interested in PolarityTE, Inc. (NASDAQ:PTE), then you might want to consider its beta (a measure of share...
Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, is investigating certain officers and directors of PolarityTE, Inc. (PTE), comScore, Inc. (SCOR), AMC Entertainment Holdings, Inc. (AMC), and Conagra Brands, Inc. (CAG) on behalf of long-term stockholders. Bragar Eagel & Squire is investigating certain officers and directors of PolarityTE, Inc. following a class action complaint that was filed against PolarityTE on June 26, 2018.
Bragar Eagel & Squire is investigating certain officers and directors of National General Holdings Corp. (NGHC), Natural Health Trends Corp. (NHTC), Omnicell, Inc. (OMCL), and PolarityTE, Inc. (PTE) on behalf of long-term stockholders. More information about each potential case can be found at the link provided. Bragar Eagel and Squire is investigating certain officers and directors of National General Holdings Corp. following a class action complaint that was filed against National General on July 25, 2019.
PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that it has received correspondence from the United States Securities and Exchange Commission ("SEC") advising PolarityTE that the SEC’s investigation relating to a range of securities, financial, personnel, and other matters has concluded. The correspondence states that, based on the information the SEC has received to date, the SEC Staff does not intend to recommend an enforcement action by the SEC against PolarityTE.
Analysts might have been a bit too bullish on PolarityTE, Inc. (NASDAQ:PTE), given that the company fell short of...
Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 750 active prominent money managers and analyze their quarterly 13F filings. The stocks that are heavily bought by hedge funds historically outperformed the market, though there is no shortage of high profile […]
PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, announced today that it will attend the Oppenheimer 30th Annual Healthcare Conference held on March 17-18, 2020 in New York, NY.
PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced the appointment of Chris Nolet to the Company’s Board of Directors and Chair of the Audit Committee. Mr. Nolet brings extensive audit and business experience with nearly forty years in the profession, most recently as the West Region Life Sciences Industry Leader and Partner at EY. Prior to EY, Mr. Nolet spent over twenty years at PricewaterhouseCoopers, where he was a partner and led the North America West Life Sciences Industry Group.